Renaissance Technologies LLC Reduces Position in Alkermes plc $ALKS

Posted by Francis Steltz on Jul 25th, 2026

Renaissance Technologies LLC trimmed its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 7.6% during the first quarter, Holdings Channel.com reports. The firm owned 6,160,428 shares of the company’s stock after selling 507,600 shares during the period. Renaissance Technologies LLC’s holdings in Alkermes were worth $217,833,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Cullen Frost Bankers Inc. acquired a new position in shares of Alkermes during the fourth quarter worth $28,000. Johnson Financial Group Inc. acquired a new stake in Alkermes in the third quarter valued at $31,000. UMB Bank n.a. raised its stake in Alkermes by 57.6% in the fourth quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after buying an additional 446 shares in the last quarter. Salomon & Ludwin LLC lifted its holdings in Alkermes by 115.6% during the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock worth $35,000 after buying an additional 667 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. lifted its holdings in Alkermes by 1,041.4% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after buying an additional 1,208 shares during the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP David Joseph Gaffin sold 2,034 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $54.03, for a total transaction of $109,897.02. Following the transaction, the executive vice president directly owned 227,490 shares in the company, valued at approximately $12,291,284.70. This trade represents a 0.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher I. Wright sold 2,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the sale, the director owned 25,680 shares of the company’s stock, valued at approximately $1,158,168. This trade represents a 7.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 35,102 shares of company stock valued at $1,494,410. 4.59% of the stock is currently owned by company insiders.

Alkermes Trading Down 0.2%

NASDAQ:ALKS opened at $52.89 on Friday. The company has a market capitalization of $8.82 billion, a PE ratio of 58.77 and a beta of 0.34. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $55.67. The stock’s 50 day moving average price is $46.92 and its 200 day moving average price is $37.44. The company has a quick ratio of 1.70, a current ratio of 2.27 and a debt-to-equity ratio of 0.85.

Analyst Ratings Changes

ALKS has been the subject of several analyst reports. Royal Bank Of Canada upped their price objective on Alkermes from $45.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 9th. TD Cowen boosted their target price on Alkermes from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Robert W. Baird upped their price target on Alkermes from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. began coverage on Alkermes in a report on Monday, July 13th. They issued a “neutral” rating and a $60.00 price target for the company. Finally, Wells Fargo & Company increased their price target on shares of Alkermes from $44.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $52.50.

Get Our Latest Stock Analysis on Alkermes

Alkermes Profile

(Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.